Publications by authors named "Antonio E Camelo-Filho"
Cerebrotendinous xanthomatosis (CTX) is a rare metabolic disorder caused by mutations in the gene, leading to cholestanol accumulation in various tissues, including peripheral nerves. Polyneuropathy is an underrecognized feature with considerable variability in clinical presentation and neurophysiological findings in CTX. This review assesses the prevalence, clinical manifestations, and diagnostic methodologies of polyneuropathy in CTX, exploring its underlying mechanisms and potential treatment outcomes.
View Article and Find Full Text PDFArticle Synopsis
- Cerebrotendinous xanthomatosis (CTX) is a rare genetic disorder causing various neurological issues, including balance problems and sleep disturbances.
- A recent study examined sleep patterns in four CTX patients, revealing significant issues like insomnia and excessive daytime sleepiness.
- This study is the first to consider sleep assessments in CTX management, highlighting the need for more research on how cholestanol deposits may affect sleep-related brain functions.
Article Synopsis
- A 34-year-old man experienced severe symptoms after a rattlesnake bite and was treated with anticrotalic serum.
- Three weeks post-bite, he developed nerve-related issues in his left hand that spread to all limbs, leading to a diagnosis of asymmetric axonal sensorimotor multiple mononeuropathy.
- After receiving prednisone treatment, he showed significant improvement in nerve function after six months, marking a rare case of post-snake envenomation peripheral neuropathy that highlights the importance of timely recognition and treatment.
Late-onset Pompe disease manifests predominantly in the proximal lower limbs and may be mistaken for an inflammatory myopathy. A 46-year-old man with acromegaly had an 8-year history of progressive weakness. His myopathy was initially attributed to the acromegaly, but severe progression prompted a muscle biopsy, which suggested an inflammatory myopathy.
View Article and Find Full Text PDFBackground: The COVID-19 pandemic has brought substantial challenges for current practices in treating hereditary neuromuscular disorders (hNMDs). However, this infection has not been the only concern for these patients. Social distancing has compromised multidisciplinary assistance and physical activity, and has brought about several mental health issues.
View Article and Find Full Text PDFObjective: To describe the clinical, neurological, neuroimaging, and cerebrospinal fluid (CSF) findings associated with encephalopathy in patients admitted to a COVID-19 tertiary reference center.
Methods: We retrospectively reviewed records of consecutive patients with COVID-19 evaluated by a consulting neurology team from March 30, 2020 through May 15, 2020.
Results: Fifty-five patients with confirmed SARS-CoV-2 were included, 43 of whom showed encephalopathy, and were further divided into mild, moderate, and severe encephalopathy groups.
Myasthenia gravis (MG), an autoimmune neuromuscular disorder, may be a risk factor for severe COVID-19. We conducted an observational retrospective study with 15 consecutive adult MG patients admitted with COVID-19 at four hospitals in São Paulo, Brazil. Most patients with MG hospitalized for COVID-19 had severe courses of the disease: 87% were admitted in the intensive care unit, 73% needed mechanical ventilation, and 30% died.
View Article and Find Full Text PDFBackground: More than one-third of COVID-19 patients present neurological symptoms ranging from anosmia to stroke and encephalopathy. Furthermore, pre-existing neurological conditions may require special treatment and may be associated with worse outcomes. Notwithstanding, the role of neurologists in COVID-19 is probably underrecognized.
View Article and Find Full Text PDF